The latest price target for Arcturus Therapeutics (NASDAQ:ARCT) was reported by Citigroup on November 13, 2025. The analyst firm set a price target for $9.00 expecting ARCT to rise to within 12 months ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Arcturus Therapeutics (NASDAQ:ARCT) traded lower on Friday after Citi downgraded the San Diego, California-based biotech, citing mid-stage data the company posted this week for ARCT-032, a messenger ...

1 Day ARCT -8.76% DJIA 0.10% Russell 2K -0.04% Health Care/Life Sciences -0.15% ...

SAN DIEGO, October 28, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

About Arcturus Therapeutics Holdings Inc. Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...

SAN DIEGO, November 04, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

Fintel reports that on October 23, 2025, Wells Fargo maintained coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Overweight recommendation. Analyst Price Forecast Suggests 450.61% ...